from an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders (5).

INNSBRUCK, Austria I April 15, 2025 I Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) ...